|Description||The sulfate salt form of LOXO-101, also called Larotrectinib, is a ATP-competitive inhibitor of tropomyosin receptor kinases and is still under Phase II clinical triall for Solid tumours. IC50: 2 - 20 nM.|
|Synonyms||LOXO-101 (sulfate); Larotrectinib sulfate; ARRY-470 sulfate; LOXO-101 sulfate; UNII-RDF76R62ID; RDF76R62ID|
|Solubility||DMSO: ≥ 31 mg/mL|
|Application||The sulfate salt form of LOXO-101 which is a ATP-competitive inhibitor of tropomyosin receptor kinases.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Loxo Oncology|
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, which activates hippocampal and striatal TrkB and TrkC, and their downstream signaling, and increas...
TPX-0005 is an orally available and potent ATP-competitive inhibitor of ALK/ROS1/TRK (IC50= 5.3 nM for SRC, IC50= 1.01 nM, 1.26 nM and 1.08 nM for mutant ALKs i...
GW 441756 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor (IC50 = 2 nM), reducing cell proliferation and potentiates the effects of chem...
Belizatinib is inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases (TRK). Belizatinib can bind to and inhibit both ALK and TRK ki...
This active molecular is a selective pan-TRK inhibitor. GNE-8525 shows potent antiproliferation activity (IC50 = 0.003 μM) and it shows in vivo antitumor effica...
ANA-12 is a selective TrkB antagonist. ANA-12 showed direct and selective binding to TrkB and inhibited processes downstream of TrkB without altering TrkA and T...
Tavilermide is a selective, small-molecule partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.
The sulfate salt form of LOXO-101, also called Larotrectinib, is a ATP-competitive inhibitor of tropomyosin receptor kinases and is still under Phase II clinica...